Median age (years) | 66.0 |
Menopausal status | |
Premenopausal | 2 (4.7%) |
Postmenopausal | 39 (90.7%) |
Not confirmed | 2 (4.7%) |
T class | |
T1 | 29 (67.4%) |
T2 | 11 (25.6%) |
T3 | 2 (4.7%) |
T4 | 1 (2.3%) |
Mean size of primary tumor, mm (95% CI) | 25.3 (18.9-31.7) |
N class | |
N0 | 24 (55.8%) |
N1 | 10 (23.3%) |
N2 | 5 (11.6%) |
N3 | 2 (4.7%) |
Missing | 2 (4.7%) |
Mean number of lymph node metastases (95% CI) | 2.2 (0.4-3.9) |
Primary distant metastases | |
No | 39 (90.7%) |
Yes | 4 (9.3%) |
HER2 expression | |
Negative | 40 (93.0%) |
Positive | 2 (4.7%) |
Missing | 1 (2.3%) |
Estrogen receptor expression | |
Negative (0%) | 1 (2.3%) |
Low (1-9%) | 0 (0%) |
Moderate (10-59%) | 0 (0%) |
High (>60%) | 41 (97.7%) |
Missing | 1 (2.3%) |
Progesterone receptor expression | |
Negative (0%) | 4 (9.3%) |
Low (1-9%) | 6 (14.0%) |
Moderate (10-59%) | 6 (14.0%) |
High (>60%) | 25 (58.1%) |
Missing | 2 (4.7%) |
Ki-67 expression | |
Negative (<5%) | 1 (2.3%) |
Low (5-14%) | 14 (32.6%) |
Moderate (15-30%) | 15 (34.9%) |
High (>30%) | 11 (25.6%) |
Missing | 2 (4.7%) |
Multifocal disease | |
Yes | 15 (35.9%) |
No | 28 (65.1%) |
Synaptophysin expression | |
Yes | 43 (100%) |
No | 0 (0%) |
Chromogranin expression | |
Yes | 30 (69.8%) |
No | 9 (20.9%) |
Not available | 4 (9.3%) |